Fatty acyl ethanolamine nutritional supplement and use thereof

Abstract

The invention relates to a fatty acyl ethanolamine nutritional supplement and application thereof. The main active component of the nutritional supplement is fatty acyl ethanolamine, the fatty acyl ethanolamine is selected from one or more of tridecane acyl ethanolamine, tetradecane acyl ethanolamine and pentadecanoic acid ethanolamine, the purity of the fatty acyl ethanolamine is higher than 95%, and the fatty acyl ethanolamine can be mixed with pharmaceutically acceptable carriers or excipients to be prepared into tablets, capsules, granules or oral liquid and the like. The nutritional supplement provided by the invention can significantly reduce body weight and body fat rate, and increase muscle content and strength at the same time.

Description

Technical field:

[0001] The present invention relates to the technical field of medicine and nutritional supplements, and in particular to fatty acylethanolamine nutritional supplements and uses thereof. Background technology:

[0002] Obesity is a major challenge facing the global public health field. According to the "Report on the Nutrition and Chronic Disease Status of Chinese Residents (2020)", according to my country's standards, the overweight rate of Chinese adults (≥18 years old) is 34.3%, and the prevalence of obesity is 16.4%; the overweight rate and obesity prevalence of adolescents aged 6 to 17 are 11.1% and 7.9%, respectively; the overweight rate and obesity prevalence of children under 6 years old are 6.8% and 3.6%, respectively. Obesity not only affects personal image, but is also closely related to an increased risk of various chronic diseases such as cardiovascular disease, diabetes and certain cancers. In recent years, weight loss drugs or nutritional supplements, such as orlistat, liraglutide, metformin, ketogenic diet, etc., have been widely used to control the weight of obese individuals. Although the use of these drugs or nutritional supplements can significantly reduce weight, they often give priority to reducing muscle mass during weight loss, resulting in muscle loss and decreased motor function, which brings additional harm to the treated subjects. Therefore, it is of great significance to find a new weight loss method that can effectively reduce weight without causing muscle loss and reduction.

[0003] In recent years, with the in-depth research of metabolomics and nutrition, more and more endogenous substances have been found to play an important role in regulating fat and muscle metabolism. Fatty acylethanolamines, as a class of fatty acid derivatives, have a wide range of functions, including reducing appetite, analgesia, relieving fatty liver and anti-inflammatory effects. However, previous studies have mainly focused on fatty acylethanolamines with carbon chain lengths of more than 16, such as oleoylethanolamine (C18:1), palmitoylethanolamine (C16:0), etc., and the biological functions of medium-chain fatty acylethanolamines with carbon chain lengths of 13-15 are still insufficient. In particular, there has been no report on the potential of C13-C15 fatty acylethanolamines in weight loss and muscle mass enhancement. Summary of the invention:

[0004] The inventor unexpectedly discovered that fatty acylethanolamine composed of C13-C15 medium-chain fatty acids not only has a significant weight loss effect in high-fat-fed obese mice, but also can increase muscle content and strength. This discovery provides a new solution for the treatment of obesity and sarcopenia.

[0005] According to one aspect of the present invention, a nutritional supplement is provided, the nutritional supplement comprising C13-15 fatty acylethanolamine. Preferably, the C13-15 fatty acylethanolamine is selected from at least one of the following: tridecanoylethanolamine, tetradecanoylethanolamine and pentadecanoic acid ethanolamine. Preferably, the mass fraction of the C13-15 fatty acylethanolamine is from 1% to 100%, preferably 10-100%, and more preferably 30-100%.

[0006] According to another aspect of the present invention, the nutritional supplement further comprises a pharmaceutically acceptable carrier or excipient. Preferably, the carrier or excipient is selected from starch, lactose, gelatin, magnesium stearate. Preferably, the nutritional supplement is in the form of oil drops, ready-made beverages, tablets, capsules, granules or oral liquids.

[0007] According to another aspect of the present invention, there is provided a use of the nutritional supplement for promoting weight loss, increasing muscle mass and strength, or preventing cardiovascular diseases.

[0008] A method for preparing the nutritional supplement comprises mixing the nutritional supplement with a pharmaceutically acceptable carrier or excipient and preparing the nutritional supplement in the form of tablets, capsules, granules or oral liquids. Preferably, the method further comprises testing the quality of the nutritional supplement to ensure that the product quality meets the relevant standards and requirements.

[0009] The present invention provides a novel method for reducing weight and increasing muscle content, which utilizes the physiological effects of C13-C15 medium-chain fatty acylethanolamines to simultaneously achieve the effects of reducing weight and increasing muscle content. This method not only has a significant weight loss effect, but also can increase muscle content and strength, thereby improving the overall health of the body. Description of the drawings:

[0010] In order to more clearly illustrate the specific implementation methods of the present application or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0011] Figure 1 The weight changes of mice are shown. (A) The effect of pentadecanoylethanolamine on the weight growth curve of animals; (B) The effect of tetradecanoylethanolamine on the weight growth curve of animals; (C) The effect of tridecanoylethanolamine on the weight growth curve of animals; (D) The effect of C13-C15 fatty acylethanolamine on the weight gain of animals within 8 weeks. ## P < 0.01, HFD group vs normal group; ***P<0.001, experimental group vs HFD group.

[0012] Figure 2 The changes in epididymal fat and subcutaneous fat weights of mice are shown. (A) Epididymal fat weight;

[0013] (B) Subcutaneous fat weight. ### P < 0.001, HFD group vs normal group; *** P < 0.001, ** P<0.01,

[0014] * P<0.05, experimental group vs HFD group.

[0015] Figure 3 Mean food intake of mice is shown. *** P < 0.001, ** P<0.01, * P<0.05, experimental group vs HFD group.

[0016] Figure 4 The whole body muscle rate, right hind limb quadriceps muscle weight and grip strength of mice are shown. (A) Muscle rate; (B) Right hind limb quadriceps muscle weight; (C) Grip strength. ### P < 0.001, ## P < 0.01, HFD group vs normal group; *** P < 0.001, ** P<0.01, * P<0.05, experimental group vs HFD group.

[0017] Figure 5 Fasting blood lipid levels of mice are shown: (A) serum TG level; (B) serum TC level; (C) serum LDL-c level. ### P < 0.001, ## P < 0.01, HFD group vs normal group;

[0018] *** P < 0.001, ** P<0.01, * P<0.05, experimental group vs HFD group. Specific implementation method:

[0019] In the inventor's previous research, we noticed some unique properties of medium-chain fatty acylethanolamine in the metabolic process. First, the metabolic pathway of medium-chain fatty acylethanolamine in the body is different from that of long-chain fatty acids, and it is more easily taken up and utilized by muscle and liver tissue. Secondly, medium-chain fatty acylethanolamine can activate a series of signal pathways related to fat metabolism and muscle growth, such as AMPK (adenylate-activated protein kinase), PGC-1α (peroxisome proliferator-activated receptor γ coactivator 1α) and mTOR (mammalian target of rapamycin protein). The activation of these signal pathways not only helps to promote fat decomposition and oxidation, but also stimulates muscle protein synthesis and muscle mass increase. Therefore, the present invention provides a nutritional supplement containing C13-C15 fatty acylethanolamine for promoting weight loss, increasing muscle content and strength. The nutritional supplement can include C13-C15 fatty acylethanolamine as an active ingredient, and a pharmaceutically acceptable carrier or excipient, such as starch, lactose, gelatin, magnesium stearate, etc., to be made into tablets, capsules, granules or oral liquids.

[0020] The nutritional supplement of the present invention has the following technical effects:

[0021] Weight loss effect: In our experiment, high-fat-fed obese mice were divided into an experimental group and a control group. The mice in the experimental group were given a certain dose of C13-C15 fatty acylethanolamine every day, while the control group was given an equal amount of placebo. After 8 weeks of feeding, the weight of the mice in the experimental group decreased by an average of about 15%, while the weight of the mice in the control group remained almost unchanged. In addition, the body fat percentage of the mice in the experimental group also decreased significantly, from the original 30% to about 20%. These results show that C13-C15 fatty acylethanolamine has a significant weight loss effect, and the weight loss effect is pentadecanoylethanolamine>tetradecanoylethanolamine>tridecanoylethanolamine.

[0022] Enhance muscle mass and strength: In addition to the weight loss effect, we also found that C13-C15 fatty acylethanolamine can significantly enhance the muscle mass and strength of mice. In the experiment, through muscle biopsy and histological analysis, we found that the diameter and number of muscle fibers in the experimental group of mice increased. In addition, through muscle strength testing, we found that the gripping and running abilities of the experimental group of mice were also significantly improved. These results show that C13-C15 fatty acylethanolamine not only helps with weight loss, but also enhances muscle mass and strength, and the effectiveness of enhancing muscles is pentadecanoylethanolamine>tetradecanoylethanolamine>tridecanoylethanolamine.

[0023] Example 1: Preparation of C13-C15 fatty acylethanolamine oil drops

[0024] Excipients and dosage

[0025] C13-C15 fatty acylethanolamine: as the main active ingredient, each unit dose (such as each bottle) contains 5-100 mg of C13-C15 fatty acylethanolamine, preferably 10-100 mg C13-C15 fatty acylethanolamine, more preferably 30-100 mg C13-C15 fatty acylethanolamine, most preferably 100 mg C13-C15 fatty acylethanolamine.

[0026] Carrier oil: Use, including but not limited to, medium chain triglycerides (MCT), olive oil, soybean oil, corn oil, tea tree oil, etc., for dissolving and stabilizing oleoylethanolamine. Preferably corn oil, olive oil or tea tree oil, more preferably corn oil or tea tree oil, most preferably corn oil. The content of the carrier oil is 0.1-10mL, preferably 0.3-5mL, more preferably 0.3-3mL, most preferably 2mL.

[0027] Antioxidants: including but not limited to vitamin E, sodium ascorbate, etc., are used to prevent oleoylethanolamine from oxidizing and deteriorating during storage and use. Preferably, sodium ascorbate. The content of the antioxidant is 0.001-0.2 g / mL, preferably 0.01-0.1 g / mL, and more preferably 0.05 g / mL.

[0028] Emulsifier: Use, including but not limited to, phospholipids, polysorbate 80, etc., to improve the stability and taste of the oil drop, preferably polysorbate 80. The content of the emulsifier is 0.1-5% v / v, preferably 0.3-2% v / v, preferably 0.5-1% v / v.

[0029] Flavoring agents: used, including but not limited to, sweeteners, flavors, etc., to improve the taste and acceptability of oil drops.

[0030] Procedure

[0031] Accurately weigh the required amount of oleoylethanolamine (10g), carrier oil (200mL), antioxidant (10g), emulsifier (1mL) and sweetener (1g). Add oleoylethanolamine to the carrier oil, heat to an appropriate temperature (such as 50-60°C), and stir until completely dissolved. Add the antioxidant to the dissolved oleoylethanolamine solution and continue stirring until uniform. Add the emulsifier to the above solution and emulsify it using an emulsifier or high-speed stirrer to form a uniform oil drop. Add flavoring agents such as sweeteners as needed and continue stirring until uniform. Use a high-pressure homogenizer to homogenize the oil drop to improve its stability and uniformity. Then fill the prepared oil drop into appropriate containers, seal and package them. Perform a quality inspection on the prepared oil drop, including indicators such as appearance, taste, and stability.

[0032] Example 2: Preparation of C13-C15 fatty acylethanolamine ready-made beverage

[0033] Excipients and dosage

[0034] C13-C15 fatty acylethanolamine: As the main active ingredient, each unit dose (such as each bottle) contains 5-100 mg of C13-C15 fatty acylethanolamine, preferably 10-100 mg C13-C15 fatty acylethanolamine, more preferably 30-100 mg C13-C15 fatty acylethanolamine, and most preferably 100 mg C13-C15 fatty acylethanolamine. Among them, the purity of tridecanoylethanolamine is>99%, manufactured by Merck (856706P), the purity of tetradecanoylethanolamine is>98%, manufactured by Merck (R425567), and the purity of pentadecanoylethanolamine is>99%, manufactured by Merck (850704P).

[0035] Cosolvent: Used, including but not limited to, medium chain monoglycerides and diglycerides, lecithin, etc., for dissolving and stabilizing fatty acylethanolamine. The content of the cosolvent is 1%-4% (w / v), preferably 1%-3% (w / v), and more preferably 1.5%-2% (w / v).

[0036] High-temperature skim milk powder: used to adjust the taste and color of the drink. The content is 3%-10% (w / v), preferably 5%-8% (w / v), and more preferably 5%-6% (w / v).

[0037] Flavoring agents: such as sucrose, fruit flavors, etc., are used to adjust the taste and flavor, wherein the sucrose content is 1%-5% (w / v), preferably 2%-3% (w / v), and the fruit flavor content is 0.001%-0.1% (w / v), preferably 0.005-0.01% (w / v).

[0038] Sodium alginate: used to improve the stability of beverages. Its content is 0.05%-0.1% (w / v).

[0039] Procedure

[0040] Add an appropriate amount of oleoylethanolamine to an appropriate amount of cosolvent, high-temperature skim milk powder and purified water, and stir thoroughly with a stirrer or magnetic stirrer until completely dissolved. Then add an appropriate amount of flavoring agents such as sucrose and fruit flavors to adjust the taste and flavor of the beverage. These flavoring agents should be fully dissolved and mixed before use. Then add an appropriate amount of stabilizer such as sodium alginate to prevent the beverage from stratification, precipitation or deterioration during storage and transportation. The mixed beverage is homogenized by a homogenizer to destroy the particles and bubbles therein, making the beverage more delicate, uniform and stable. Then use a pasteurization method, such as heating the beverage to 80°C for 15 seconds. Finally, fill the sterilized beverage into appropriate containers, seal and package them. The packaging material should meet food safety standards and have good sealing and barrier properties.

[0041] Example 3: Preparation of C13-C15 fatty acylethanolamine soft gelatin capsules

[0042] C13-C15 fatty acylethanolamine is dissolved in corn oil (food grade) at a concentration of 30-100 mg / mL, preferably 50-100 mg / mL, more preferably 100 mg / mL. The C13-C15 fatty acylethanolamine-corn oil solution is then sealed in a #20 oval soft gelatin capsule using standard soft gelatin strip technology / molding technology, so that each capsule contains approximately 1 mL of oil.

[0043] Example 4: Preparation of C13-C15 fatty acylethanolamine tablets and granules

[0044] C13-C15 fatty acylethanolamine: as the main active ingredient, each unit dose (such as each bottle) contains 5-100 mg of C13-C15 fatty acylethanolamine, preferably 10-100 mg C13-C15 fatty acylethanolamine, more preferably 30-100 mg C13-C15 fatty acylethanolamine, most preferably 100 mg C13-C15 fatty acylethanolamine.

[0045] Filler: Lactose, microcrystalline cellulose, etc. are used as fillers to increase the volume and weight of the tablet. The filler is preferably microcrystalline cellulose.

[0046] Binder: Use hydroxypropyl methylcellulose, polyvinyl pyrrolidone, etc. to increase the bonding force between materials so that the tablets are not easy to loosen during tableting. The amount of binder is 1%-10% w / w. Preferably 5% w / w.

[0047] Lubricant: Use magnesium stearate to reduce the friction between the material and the mold, making the tablets easier to demold. The amount of lubricant is 0.1%-1% w / w, preferably 0.5% w / w.

[0048] Disintegrants: Cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, etc. are used to promote the disintegration of tablets in the body and release of drugs. The amount of disintegrant is 5%-20% w / w, preferably 10% w / w.

[0049] Procedure

[0050] C13-C15 fatty acylethanolamine and various auxiliary materials are weighed and mixed uniformly according to a predetermined ratio. The mixture is poured into a tablet mold of appropriate size, wherein each tablet contains about 100 mg of C13-C15 fatty acylethanolamine. Alternatively, the mixture is mixed using a V-type mixer and granules are prepared using a rotary granulator (milling blade speed 52 r / min, press blade speed 55 r / min, No. 3 screen), wherein each gram of granules contains about 100 mg of C13-C15 fatty acylethanolamine.

[0051] Example 5: High-fat feeding obese mice experiment

[0052] Eight-week-old male C57BL / 6 mice were purchased from Weitong Lihua Experimental Animal Center (Beijing) and randomly divided into a normal control group, a model control group, a positive drug liraglutide group, and an experimental observation group. The blank control group was given a standard mouse diet, and the other groups were given a high-fat diet. The blank control group and the model control group were gavaged with the same volume of solvent every day, and the positive control group was subcutaneously injected with liraglutide every day. Tridecanoylethanolamine, tetradecanoylethanolamine, and pentadecanoylethanolamine were dissolved in corn oil at 50 mg / kg and 100

[0053] The mice were given oral administration at a dose of 100 mg / kg. The experimental period was 8 weeks. After the experiment, the weight, body fat percentage, muscle content, strength and other indicators of the mice were measured and statistically analyzed.

[0054] Experimental animal grouping: The mice were randomly divided into normal control group (NC), model control group (HFD), positive drug group (liraglutide, 100 μg / kg), low-dose pentadecanoylethanolamine group (PE-L, 50 mg / kg), high-dose pentadecanoylethanolamine group (PE-H, 100 mg / kg), low-dose tetradecanoylethanolamine group (TAE-

[0055] L, 50 mg / kg), tetradecanoylethanolamine high-dose group (TAE-H, 100 mg / kg), tridecanoylethanolamine low-dose group (TRE-L, 50 mg / kg), tridecanoylethanolamine high-dose group (TRE-H, 100 mg / kg).

[0056] There were 10 mice in each group.

[0057] Administration: The blank control group and the model control group were gavaged with the same volume of corn oil every day, and the positive control group was subcutaneously injected with liraglutide every day. Tridecanoylethanolamine, tetradecanoylethanolamine and pentadecanoylethanolamine were dissolved in corn oil and gavaged at doses of 50 mg / kg and 100 mg / kg.

[0058] Experimental period and observation indicators: The experimental period was 8 weeks. The body weight and food intake of the animals were recorded every week. In the 8th week of the experiment, the grip strength of the mice was measured. The day before the end of the experiment, the animals were fasted overnight, and then the body fat rate and muscle content of the mice were tested using the Bruker Minispec LF50 body composition analyzer. The animals were then killed, whole blood was taken, and serum was separated for blood lipid level testing. At the same time, the epididymal fat and subcutaneous fat of the right hind limb of the animals were weighed, and the quadriceps femoris of the right hind limb was weighed.

[0059] Mouse grip strength measurement:

[0060] The grip strength of mice was measured using the XR501 rat grip dynamometer provided by Shanghai Xinruan Information Technology Co., Ltd. Two days before the end of the experiment, each group of mice fasted for 6 hours, and then the grip strength of the mouse forelimbs was tested according to the grip dynamometer operating instructions. In short, the mouse was placed on the metal cage of the grip dynamometer and the mouse tail was grasped so that the mouse limbs grasped the grid tightly. The mouse tail was gently pulled until it completely released the grip dynamometer grid, and the grip dynamometer reading was recorded. Each mouse was tested 3 times, and the average value was taken for statistical analysis.

[0061] Data statistical analysis: The experimental data were expressed as mean ± standard error. SPSS14.0 was used to perform statistical analysis on the experimental data, and variance analysis was used to compare whether the differences between the experimental group and the control group were statistically significant.

[0062] Experimental results:

[0063] 1. Anti-obesity effect of C13-C15 fatty acylethanolamine on high-fat diet-induced obesity in mice

[0064] Oral administration of C13-C15 fatty acylethanolamines showed excellent weight loss effects. Figure 1 As shown in A-1C, compared with normal mice, the weight of mice in the high-fat diet group (HFD) increased rapidly and was significantly higher than that of normal mice. Figure 1 A), tetradecanoylethanolamine ( Figure 1 B) and tridecanoylethanolamine ( Figure 1 C), slowing down the weight gain of the animals, and eventually their body weight was significantly lower than that of the HFD group ( Figure 1D). In terms of weight loss efficacy, pentadecanoylethanolamine showed the strongest weight loss effect, and 100 mg / kg of pentadecanoylethanolamine performed similarly to 100 μg / kg of liraglutide, followed by tetradecanoylethanolamine and tridecanoylethanolamine ( Figure 1 D). Accordingly, oral administration of C13-C15 fatty acylethanolamine significantly reduced the amount of fat accumulation in animals. Whether it was epididymal fat or subcutaneous fat, oral administration of C13-C15 fatty acylethanolamine showed a stronger reducing effect than liraglutide ( Figure 2 A-2B). In general, the ability of the three fatty acylethanolamines to reduce fat accumulation is pentadecanoylethanolamine>tetradecanoylethanolamine>tridecanoylethanolamine>liraglutide. In terms of diet, oral administration of C13-C15 fatty acylethanolamine can significantly reduce the food intake of animals. High doses (100 mg / kg) of C13-C15 fatty acylethanolamine can significantly reduce the food intake of mice ( Figure 3 ), suggesting that C13-C15 fatty acylethanolamine can suppress the appetite of animals. In summary, C13-C15 fatty acylethanolamine can effectively reduce the body weight of mice, reduce the weight of subcutaneous and epididymal fat, and has a significant weight loss effect.

[0065] 2. Muscle-enhancing effect of C13-C15 fatty acylethanolamine on mice

[0066] During weight loss, muscle loss often takes precedence over fat tissue, resulting in a significant decrease in muscle mass while losing weight. Figure 4 As shown in the figure, the muscle rate of animals in the high-fat diet group was significantly lower than that in the normal group. Although liraglutide showed a strong effect in reducing body weight, it also caused muscle loss. The muscle rate of animals ( Figure 4 A) Right hind limb quadriceps weight ( Figure 4 B) were significantly lower than those in the HFD group, which ultimately led to a decrease in the animals' grip strength ( Figure 4 C). Surprisingly, although C13-C15 fatty acylethanolamine also showed good weight loss effects, its muscle content was significantly increased ( Figure 4 A-4B), and eventually the animals' gripping strength also improved significantly ( Figure 4 C) Overall, pentadecanoylethanolamine has the strongest muscle-building ability, followed by tetradecanoylethanolamine and tridecanoylethanolamine.

[0067] 3. Effects of C13-C15 fatty acylethanolamine on blood lipids in mice

[0068] Obesity is often accompanied by elevated blood lipids, which increases the risk of cardiovascular disease. Figure 5As shown in the figure, the serum TC, TG and LDL-c levels in the HFD group were significantly higher than those in the normal group. Oral administration of C13-C15 fatty acylethanolamines can significantly reduce the blood lipid levels of obese animals. For serum TG, 100 mg / kg of pentadecanylethanolamine and tridecanoylethanolamine can significantly reduce the level of TG, but 50 mg / kg of pentadecanylethanolamine and tridecanoylethanolamine and 50 mg / kg and 100 mg / kg of tetradecanoylethanolamine did not significantly reduce the TG level of animals ( Figure 5 A). For serum TC and LDL-c, 100 mg / kg of pentadecanoylethanolamine, tetradecanoylethanolamine and tridecanoylethanolamine significantly reduced their serum levels, and their efficacy was better than liraglutide. Especially for the level of LDL-c, 50 mg / kg and 100 mg / kg of C13-C15 fatty acylethanolamine were able to significantly reduce its content ( Figure 5 B and 5C). Therefore, C13-C15 fatty acylethanolamines show a stronger ability to reduce serum TC and LDL-c, thus helping to prevent the occurrence of cardiovascular diseases.

[0069] The experimental results showed that the weight and body fat percentage of the experimental group mice were significantly reduced, the muscle content and strength were significantly increased, and the blood lipid level was significantly reduced. Compared with the control group, the weight loss effect and muscle strengthening effect of the experimental group mice were statistically significant.

[0070] The present invention provides a new method for losing weight and increasing muscle content, which utilizes the physiological effect of 15-carbonic acid to achieve the effect of losing weight without losing muscle mass and increasing muscle strength. The present invention provides important scientific basis and technical support for the development of new weight loss and fitness products.

[0071] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A nutritional supplement, characterized in that: The nutritional supplement comprises C13-15 fatty acylethanolamine.

2. The nutritional supplement according to claim 1, characterized in that The C13-15 fatty acylethanolamine is selected from at least one of tridecanoylethanolamine, tetradecanoylethanolamine and pentadecanoic acid ethanolamine.

3. The nutritional supplement according to claim 1 or 2, wherein the mass fraction of the C13-15 fatty acylethanolamine is 1% to 100%.

4. The nutritional supplement according to claim 1 or 2, wherein the mass fraction of the C13-15 fatty acylethanolamine is 10-100%.

5. The nutritional supplement according to claim 1 or 2, wherein the mass fraction of the C13-15 fatty acylethanolamine is 30-100%.

6. The nutritional supplement according to claim 1 or 2, further comprising a pharmaceutically acceptable carrier or excipient, wherein the carrier or excipient is selected from starch, lactose, gelatin, and magnesium stearate.

7. The nutritional supplement according to claim 1 or 2, characterized in that: The nutritional supplement is in the form of oil drops, ready-made beverages, tablets, capsules, granules or oral liquids.

8. Use of the nutritional supplement according to any one of claims 1 to 7 to promote weight loss, increase muscle mass and strength, or prevent cardiovascular disease.

9. A method for preparing the nutritional supplement according to any one of claims 1 to 7, characterized in that: The method comprises mixing the nutritional supplement with a pharmaceutically acceptable carrier or excipient and preparing the nutritional supplement in the form of oil drops, ready-made beverages, tablets, capsules, granules or oral liquids.

10. The method according to claim 9, characterized in that The method further comprises conducting quality inspection on the prepared nutritional supplement to ensure that the quality of the nutritional supplement meets relevant standards and requirements.

Images